PPARγ agonist efatutazone and gefitinib have been indicated to synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway [34]. This evidence concerns the gene AKT1 and lung adenocarcinoma.